Intra-Cellular Therapies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Net Income	-74.68	-139.67	-256.26	-284.13	-227.01	Upgrade
Depreciation & Amortization	0.51	0.53	0.66	0.53	0.53	Upgrade
Loss (Gain) From Sale of Investments	-9.03	-8.4	0.45	-4.08	-0.65	Upgrade
Stock-Based Compensation	64.12	52.92	43.1	34.48	24.33	Upgrade
Change in Accounts Receivable	-52.48	-38.83	-55.03	-9.39	-10.77	Upgrade
Change in Inventory	-14.91	-26.35	-15.97	-0.89	-7.06	Upgrade
Change in Accounts Payable	14.62	1.06	1.7	3.19	-1.92	Upgrade
Change in Other Net Operating Assets	-1.33	34.54	11.17	0.74	-7.8	Upgrade
Operating Cash Flow	-73.18	-124.2	-270.19	-259.54	-230.07	Upgrade
Capital Expenditures	-0.32	-0.27	-0.78	-0.33	-0.27	Upgrade
Investment in Securities	-334.83	105.81	-127.6	280.67	-480.03	Upgrade
Investing Cash Flow	-335.15	105.54	-128.37	280.34	-480.3	Upgrade
Issuance of Common Stock	567.51	17.81	455.16	11.52	664.18	Upgrade
Financing Cash Flow	567.51	17.81	455.16	11.52	664.18	Upgrade
Net Cash Flow	159.18	-0.85	56.6	32.32	-46.19	Upgrade
Free Cash Flow	-73.5	-124.47	-270.96	-259.87	-230.34	Upgrade
Free Cash Flow Margin	-10.79%	-26.80%	-108.25%	-310.10%	-1009.69%	Upgrade
Free Cash Flow Per Share	-0.71	-1.30	-2.88	-3.20	-3.27	Upgrade
Cash Income Tax Paid	1.82	0.16	0.01	0.01	0	Upgrade
Levered Free Cash Flow	-63.55	-28.97	-180.85	-150.04	-148.8	Upgrade
Unlevered Free Cash Flow	-63.55	-28.97	-180.85	-150.04	-148.8	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.